Aflibercept

Products

Aflibercept is marketed as an injectable (Eylea). It was approved in many countries in 2012.

Structure and properties

Aflibercept (C4318H6788N1164O1304S32) is a recombinant fusion protein consisting of the extracellular portions of human VEGF receptor 1 and 2 coupled to the Fc receptor of human IgG1.

Effects

Aflibercept (ATC S01LA05) binds the growth factors VEGF-A (vascular endothelial growth factor-A) and PlGF (placental growth factor), which contribute to blood vessel formation and increased vascular permeability. It is a soluble receptor for the two growth factors and serves as a “decoy” to inactivate them.

Indications

Dosage

According to the professional information. The drug is administered intravitreally, that is, into the vitreous humor of the eye.

Contraindications

  • Hypersensitivity
  • Infections in the eye or in the area around the eye
  • Acute inflammation of the eye

For complete precautions, see the drug label.

Interactions

There are no known interactions with other drugs.

Adverse effects

The most common possible adverse effects include conjunctival hemorrhage, eye pain, cataracts, vitreous detachment, mouches volantes, and increased intraocular pressure.